MARKERS ASSOCIATED WITH HUMAN DOUBLE MINUTE 2 INHIBITORS

摘要

The invention provides methods of monitoring differential gene expression of biomarkers to determine patient sensitivity to Human Double Minute inhibitors (MDM2i), methods of determining the sensitivity of a cell to an MDM2i by measuring biomarkers and methods of screening for candidate MDM2i.

主权项

1. A method of predicting the sensitivity of a cancer patient for treatment with a Human Double Minute 2 inhibitor (MDM2i), the method comprising:
a) measuring differential gene expression of at least one biomarker selected from Table 2 in a cancer sample obtained from the patient; and b) comparing the differential gene expression of the at least one biomarker with gene expression of said biomarker in a control sample, wherein the increase or decrease in gene expression comparison indicates that the patient is sensitive to treatment with an MDM2i.